Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes
Krishan R. Jethwa(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Thomas J. Whitaker(Mayo Clinic), E. Tryggestad(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Broc Giffey(Mayo Clinic), Kenneth W. Merrell(Mayo Clinic), Bret D. Kazemba(Mayo Clinic)
Cited by 29
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
|Journal of Clinical Oncology|2008|270
Oesophageal cancer
|The Lancet|2024|265